John Jordan

Director Financiero/CFO en Rna Diagnostics, Inc. .

Health Technology

Perfil

John Jordan has held positions as a Chief Financial Officer and Director at Rna Diagnostics, Inc. and as a Director and Chief Financial Officer at Proteocyte Diagnostics, Inc. Currently, Mr. Jordan holds positions at both companies as their Chief Financial Officer and Director.

Cargos activos de John Jordan

Empresas	Cargo	Inicio
Rna Diagnostics, Inc. Rna Diagnostics, Inc. Medical SpecialtiesHealth Technology Rna Diagnostics, Inc. operates as a cancer diagnostics company which builds a platform of prognostic biomarker tools to help improve the lives of patients undergoing chemotherapy. The firm develops prognostic biomarker tools to improve the lives of women undergoing chemotherapy for breast cancer. It provides The RNA Disruption Assay (RDA), which provides physicians with an evaluation of how individual patients are responding to chemotherapy. The company was founded by Kenneth P. H. Pritzker in 2010 and is headquartered in Toronto, Canada.	Director Financiero/CFO	-
Proteocyte Diagnostics, Inc. Proteocyte Diagnostics, Inc. Medical SpecialtiesHealth Technology Proteocyte Diagnostics, Inc. develops prognostic oral precancer laboratory, which objectively and accurately detects oral lesions. The company was founded in 2011 and is headquartered in Toronto, Canada.	Director Financiero/CFO	-

Todos los cargos activos de John Jordan

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de John Jordan.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas privadas	2
Rna Diagnostics, Inc. Rna Diagnostics, Inc. Medical SpecialtiesHealth Technology Rna Diagnostics, Inc. operates as a cancer diagnostics company which builds a platform of prognostic biomarker tools to help improve the lives of patients undergoing chemotherapy. The firm develops prognostic biomarker tools to improve the lives of women undergoing chemotherapy for breast cancer. It provides The RNA Disruption Assay (RDA), which provides physicians with an evaluation of how individual patients are responding to chemotherapy. The company was founded by Kenneth P. H. Pritzker in 2010 and is headquartered in Toronto, Canada.	Health Technology
Proteocyte Diagnostics, Inc. Proteocyte Diagnostics, Inc. Medical SpecialtiesHealth Technology Proteocyte Diagnostics, Inc. develops prognostic oral precancer laboratory, which objectively and accurately detects oral lesions. The company was founded in 2011 and is headquartered in Toronto, Canada.	Health Technology